New York – October 10, 2014 – Cooley advised the underwriters on Vitae Pharmaceuticals, Inc.'s initial public offering. Vitae Pharmaceuticals is a clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs to address significant unmet medical needs. The company now trades on The NASDAQ Global Stock Market under the symbol "VTAE."
The underwriters for the offering were Stifel, Nicolaus & Company, Incorporated, BMO Capital Markets Corp., JMP Securities LLC and Wedbush Securities Inc.
The Cooley corporate and securities team advising the underwriters was comprised of partners Bo Yaghmaie, Div Gupta and Stephane Levy, special counsel Tom Twedt and associates Steve Bielecki and Ariana Green.
Critical support for the offering was provided by partner Thomas Welk (compensation & benefits); partner Thomas Blinka and associate Sandhya Deo (intellectual property); partner Seth Rafkin and associate Andrew Turnbull (employment & labor); partners Wendy Goldstein and Natasha Leskovsek, special counsel Phil Mitchell and associate Jennifer Shanley (health care and life sciences regulatory); partner Kenneth Krisko and associate Jennifer Raab (life sciences transactions); partner Jeremy Naylor (tax); and associate Brendan Koeth (mergers and acquisitions).
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has 800 lawyers across 11 offices in the United States and China.